Provista Diagnostics to Participate in BTIG’s Inaugural Emerging Technologies in Healthcare Diagnostics Symposium

New York, NY – September 26, 2014 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic, prognostic and monitoring Laboratory Developed Tests (LDTs) designed to address the unmet needs in breast and gynecologic cancers affecting women, announces that David Reese, PhD, President and Chief Executive Officer is scheduled to participate in the inaugural BTIG Emerging Technologies in Healthcare Diagnostics Symposium being held September 29-30, 2014 at The Benjamin Hotel in New York City.

During the symposium, Dr. Reese will participate on a panel entitled, “Symptomatic Oncology – Innovations in Blood Testing,” which will convene at 1:10 PM EDT on Monday, September 29^th. As part of the symposium, leading diagnostic companies will present on a series of thematic panels to familiarize attendees with the diagnostic space, associated technologies, and foster an understanding of how the tools work and why they should be adopted. Participants in the conference include both publicly-traded and private companies.

Provista is currently working with world-class research institutions to conduct rigorous prospective clinical trials to evaluate the clinical utility of a breast cancer detection test. Recently, Provista completed a second prospective trial and currently is halfway through enrollment of a third prospective trial in patients with suspicious breast masses.   The studies are designed to utilize Provista’s proprietary blood test in conjunction with standard-of-care to help assess the presence of breast cancer in patients with suspicious breast lesions. When this breast test is commercially available, Provista will have data from three prospective, randomized clinical trials with more than 1,350 patients from 15 breast centers across the U.S.

About Provista

Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at ProvistaDx.com

Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

###